FDA Committee OKs Psoriasis Drug For Kids

Law360, New York (June 20, 2008, 12:00 AM EDT) -- A U.S. Food and Drug Administration advisory committee has narrowly voted to recommend that the agency approve Amgen Inc.'s Enbrel for children despite concerns that the medication could cause serious side effects.

The advisory committee voted 8-5 on Wednesday in favor of allowing children to take Enbrel, which is used to treat the skin disease psoriasis, finding that the benefits of the medication outweigh the risks, Reuters reported.

Amgen and Wyeth, which co-markets the drug, were forced to add the strongest possible warning to the package...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.